Available Online at www.ijpba.in

International Journal of Pharmaceutical and Biological Science Archive 1 (1) 2013, 01-10

REVIEW ARTICLE

IMPERATIVE HIGHLIGHTS OF THERAPEUTIC MICRORNA STRATEGIES IN CANCER AND STEM CELLS

Pramod Khatri

Genetics Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi 110029, India

Received 10 May 2013; Revised 15 May 2013; Accepted 30 May 2013

ABSTRACT

MicroRNAs (miRNAs) are a class of endogenous non-protein-coding RNAs that function as paramount regulatory molecules by adversely managing gene and protein expression through the RNA interference (RNAi) mechanism. MiRNAs have been ensnared to control an assortment of cellular, physiological, and developmental courses of action. Unusual expression of miRNAs is amalgamated with human maladies, for example cancer. Tumor stem cells are an insignificant subpopulation of cells identified in an assortment of tumors that are equipped for self-recreation and separation. Dysregulation of stem cell self-replenishment is a possible necessity for the start and creation of cancer. Moreover, tumor stem cells are a quite likely explanation for imperviousness to current cancer medicines, and additionally regress in tumor patients. Comprehension the biology and pathways included with tumor stem cell offers extraordinary assurance for advancing better tumor remedies, and may one day even give a cure for tumor. Rising proof shows that miRNAs are included in tumor stem cell dysregulation. Latest studies additionally recommend that miRNAs assume a basic part in carcinogenesis and oncogenesis by managing cell burgeoning and apoptosis as oncogenes or tumor silencers, separately. Thusly, molecularly focused on miRNA treatment could be an effective device to rectify the tumor stem cell dysregulation.

KEYWORDS: cancer stem cells, microRNAs, oncogenes, tumor suppressors.

INTRODUCTION:

MICRORNA EVOLUTION:

MiRNAs and small interfering RNAs (siRNAs) are two crux parts of RNA interference inside the cell. siRNAs are determined by transforming of long twofold stranded RNAs and are regularly of exogenous root and degrade mRNAs bearing completely integral sequences [1]. Conversely, miRNAs are endogenously encoded modest noncoding RNAs, determined by preparing of short RNA barrettes, which can repress the interpretation of mRNAs bearing moderately reciprocal target successions [1]. miRNAs are endogenous and regularly created in animal cells. Hence, the utilization of miRNAs is more appropriate in improving therapeutics that can control mRNA in animal cells.

MiRNA evolution has been contemplated by numerous investigators. A schematic outline of miRNA evolution is given in Fig. 1. MiRNAs are interpreted by RNA polymerase II enzyme preparing a long essential miRNA (pri-miRNA) [2]. These pri-miRNAs hold a cap structure at the 5′ closure and are poly-adenylated at the 3′ closure, advising that pri-miRNAs are structurally and practically comparable to mRNAs [3]. Likewise, pri-miRNAs hold specific hairpin molded stem-loop structures of ~70 nucleotides that are distinguished and cut by a ~650-kDa atomic microprocessor chip complex comprising of the RNAase III endonuclease Drosha and the fundamental DiGeorge syndrome critical region gene 8 (DGCR8) binding protein [4]. The subsequent ~70 nucleotide hairpin intermediate (pre-miRNA) is transported out of the nucleus core and into the cytoplasm by Exportin-5 and its cofactor Ran-GTP [5]. In the cytoplasm, the pre-miRNAs are further divided by a second RNAase III endonuclease Dicer-1 and its crucial trans activating reaction RNA binding protein (TRBP) transforming a short blemished twofold stranded miRNA duplex. The flawed miRNA duplex is then unwound into a developed miRNA by helicase. Afterward, TRBP recruits the synergist Argonaute 2 to the Dicer intricate with the full grown miRNA framing the RNA-induced silencing complex (RISC) [6,] . RISC then controls gene articulation by mRNA degradation or translational suppression [7]. Subsequently, miRNAs contrarily direct gene and protein outflow through the RNA interference (RNAi) pathway. miRNA is not quite

*Corresponding author: Pramod Khatri | Email: pramodsinghkhatri@gmail.com

the same as siRNA in that miRNA quells mRNA with corresponding sequence in the 3'-untranslated region (3'-UTR) [8], in spite of the fact that miRNA may likewise target coding areas of mRNA, regardless in animals [9].

MICRORNA AND DIRECTIVE OF STEM CELLS:

MiRNAs have been proposed to be significant variables in stem cell capacity. One purpose behind this is that expression levels of certain miRNAs in stem cells are not quite the same as other standard tissues [10]. This intimates that miRNAs may have a remarkable part in stem cell regulation. Keeping in mind the end goal to confirm that miRNAs do without a doubt manage stem cell capacity, numerous researchers have utilized Dicer-1 (dcr-1) mutants. Dicer-1 assumes a particular part in the biogenesis of miRNAs and hence can offer incredible understanding into the part of miRNAs in stem cell. Loss of dcr-1 function in rodent model brought about animal decease premature development and consumption of stem cells in rodent embryo, proposing that the disrupted miRNA pathway assumes an extensive part in looking after the stem cell populace [11]. Mutated dcr-1 gene in embryonic stem cell in rodents expedites a diminished interpretation of miRNAs and showed intense defect in embryonic stem cell separation in vivo and in vitro. Re-interpretation of Dicer-1 in the knockout cells recovered the phenotypes [12]. A different study watched a decrease in cyst production in Drosophila germ line stem cell mutants for dcr-1 and a postponement in the transition from G1 to S stage, which is subject to the cyclin-dependent kinase inhibitor Dacapo [13]. This finding that miRNAs are needed for stem cell division infers that miRNAs are requested to make stem cells harsh to ecological indicators to beat the typical G1/s checkpoint [13]. The utilization of dcr-1 mutants has brought good amount of information and findings that ensnare the imperative part that miRNAs play in stem cell capacity.

TUMOR STEM CELL ASSUMPTION:

Stem cells are defined by their capability to experience self-reestablishment, and also multi-ancestry separation [14]. Adult stem cells are discovered in various tissues of the body and assume a part in tissue advancement, displacement, and repair [15]. In this review, tumor cells are defined as cells that are part of a cancer. Latestly, there has been a dramatic exploration adapted towards a small subpopulation of cells identified in cancer that have stem cell properties. The cancer stem cell theory recommends that cancer are inferred from a little division of tumor cells that constitute a supply of self-maintaining cells with the restrictive capability to self-restore and initiate/maintain the tumor [16]. Consequently, consistent with the cancer stem cell speculation, these cancer stem cells are tumor-starting cells that burgeon through their special self-recharging capability. Cancer stem cells were first identified in leukemia [17]. As of late, numerous researchers have identified cancer stem cells in robust tumors incorporating breast, cerebrum, pancreas, colon, and head and neck cancer [18]. These new findings furnish further support for the cancer stem cell theory. In a few sorts of human cancer, for example melanoma, such tumorigenic cells may not be uncommon [19].

The cancer stem cell theory made a premise for future thinks about, and also displayed an improved comprehension of the biology science and intricacies of cancer and tumor framing. To be maximally adequate, cancer treatment must additionally be regulated against both the resting cancer stem cells and the burgeoning cancer cells. This may be conceivable if specific stem cell signal are restrained utilizing molecular treatment, while in the meantime striking growing cells by accepted therapies [20].

SELF-REPLENISHMENT:

Utilizing diverse frameworks, numerous researchers have revealed that just a modest minority of cells in human cancer are fit for self-recharging. Self-replenishment is recognized from other expanding courses of action in that no less than one of the offspring is indistinguishable to the initial stem cell . Specifically, unbalanced stem cell self-reestablishment produces two distinctive descendants. The first descendants is indistinguishable to the original stem cell in this manner, administering stem cell number—and the other offspring transformed is a bound progenitor cell, which experiences cell separation . Both the self-replenishment and separation of standard stem cells are directed by the stem cell microenvironment, which has been termed the stem cell corner [21]. Keeping in mind the end goal to study the self-recharging potential, a mammosphere examine has been created that plates cells in a serum free medium with cancer factor consider supplementation on a non-disciple substrata emulated by quantification of circle framing [22]. Utilizing this strategy, one study discovered that secondary mammospheres from the human breast cancer Lin−$CD29^{h}CD24^{h}$ cell subgroup as dead set from seven autonomous tumors were bigger in size and number contrasted with all different subpopulations, prescribing the capability for tumor-starting cells to experience self-replenishment [22]. Consequently, a certain subpopulation of cancer cells has the capacity to self-replenish and launch tumor creation, consequently authoring the expression "cancer stem cells." The centermost characteristic of cancer stem cells is this moderately unrestricted asymmetric self-reestablishment . Self-restoration of cancer stem cell could be a possible explanation for

resistance of current cancer medicine, and backslide in cancer patients. One latest study gave the first clinical confirmation for the suggestion of a "gliomas stem cell" or "self-reestablishment" phenotype in medicine resistance of glioblastoma [23]. It is accepted that hereditary modifications reason dysregulation in cancer stem cells, bringing about unrestricted self-replenishment proficiencies. Atypical cell self-recharging is a conceivable prerequisite for the start, structuring and resistance of cancer.



Figure 1: An outline of miRNA evolution. MiRNAs are a class of endogenous non- protein-coding RNAs that negatively regulate gene and protein expression via the RNAi pathway.

SIGNALING PATHWAYS OF THE "STEM CELL GENES:

There is developing confirmation that delineates that numerous pathways traditionally joined with cancer may likewise manage typical stem cell advancement [24]. The crucial signaling pathways of the "stem cell genes" Notch, Hedgehog, Wnt/β-catenin, HMGA2, Bcl-2, and Bmi-1 are included in the regulation of self-restoration, separation, and survival of cancer stem cells(Figure 2) .These crux signaling pathways, which may be dysregulated in tumor stem cells, offer incredible guarantee for future cancer treatments and medicines.

NOTCH:

The Notch signaling pathway is a short-reach communication transducer that is included in controlling numerous cell forms throughout improvement and reestablishment of mature tissues. Notch signaling has been highlighted as a pathway that helps being developed of the breast and is often times dysregulated in intrusive breast cancer [18]. It was likewise exhibited that Notch signaling can follow mammary stem cells to push self-replenishment and on promptly forebear cells to push their multiplication [28]. These impacts were additionally indicated to be totally repressed by either a Notch 4 neutralizer or a gamma secretase inhibitor that blocks Notch processing [28]. These findings infer that atypical Notch signaling could

expedite dysregulation of the self-reestablishment properties of cancer stem cells, in this way bringing about carcinogenesis and oncogenesis [25].

HEDGEHOG:

The significance of Hedgehog signaling in carcinogenesis spins around Hedgehog's impact on tumor stem cell self-replenishment. Hedgehog (specifically Sonic Hedgehog) signaling has been involved in the regulation of self-restoration characteristics by the finding that populaces advanced for human hematopoietic stem cells show expanded self-replenishment according to Sonic Hedgehog stimulation in vitro, but in combo with other cancer elements [26]. In people, some different cancers, incorporating basal-cell carcinoma, come about because of changes that unusually actuate Hedgehog indicator transduction. It has been indicated that Drosophila ovarian stem cell can't mushroom as stem cells without Hedgehog signaling, inasmuch as unreasonable Hedgehog signaling produces supernumerary stem cells, suggesting that Hedgehog is a stem cell variable [27]. This recommends that human cancers because of unreasonable Hedgehog signaling may come about because of dysregulated self-restoration properties of cancer stem cells.

WNT/β-CATENIN:

A different pathway that manages both self-replenishment and oncogenesis in distinctive tissues is the Wnt/β-catenin signaling pathway . Actuation of the Wnt receptor makes a collection of β-catenin and other Wnt gene family proteins in the cytoplasm, which at the end of the day translocates into the core. The nuclear translocation of β-catenin drives the interpretation of genes connected with self-replenishment. Over-expression of initiated β-catenin grows the pool of stem cells [28]. Dysregulation in the Wnt/β-catenin signaling pathway gives to the onset of cancer. Gain or loss-of-capacity transformations of a few parts of this pathway have been discovered in numerous sorts of human tumors [29]. A different study indicated that, in incessant myelogenous leukemia, β-catenin gathers in the cores of granulocyte–macrophage progenitors, obviously upgrading the self-replenishment movement and leukemic potential of these cells [30]. Therefore, dysregulation of this pathway inside cancer stem cells may be connected with the obtaining of self-restoration properties.

HMGA2:

HMGA2 has likewise been involved in survival and self-recharging of cancer stem cells. HMGA2 is thought to assume a part in balancing macromolecule buildings that are included in numerous biotic methods, incorporating binding straightforwardly to the DNA and supporting in the regulation of numerous genes [31]. The articulation of HMGA proteins throughout embryogenesis recommends that they have paramount capacities being developed [31]. Besides, the HMGA2 gene is recommended to control development, multiplication, and separation [31]. HMGA2 has likewise been ensnared in cancer. HMGA2 overexpression has been discovered in lung and pancreatic carcinomas [32]. HMGA2 protein overexpression is frequently met with the vicinity of metastasis and decreased survival of the cancer patient [31]. Along these lines, HMGA2's function in embryogenesis and combative cancers prescribes that human cancer because of exorbitant HMGA2 signaling may come about because of dysregulated cell survival and self-recharging properties of cancer stem cells.

BMI-1:

The significance of Bmi-1 signaling in carcinogenesis rotates around Bmi-1's impact on cancer stem cell self-replenishment. Bmi-1 was indicated to be communicated in neural stem cell and mushrooming progenitor cells, however not in distinguished cells. Misfortune of Bmi-1 brought about an extreme diminishing in neural stem cell expansion and self-recharging . This recommends that Bmi-1 is fundamental for stem cell self-reestablishment. Bmi-1 has likewise been embroiled in cancer. Bmi-1 was identified to advertise the era of lymphomas [33]. This shows that Bmi-1 assumes a part in tumor improvement. Bmi-1 appears to be essential in both stem cells and cancer. Bmi-1 was discovered to be enacted in human breast "cancer stem cells" portrayed as $CD44^{+}CD24^{-/low}Lin-$ [34]. Besides, Bmi-1 was discovered to intervene the mammosphere-starting cell number and mammosphere size, supporting a part in the regulation of self-restoration of ordinary and tumorigenic human mammary stem cells [34]. In this manner, dysregulation of this Bmi-1 pathway inside cancer stem cells may be connected with the obtaining of self-replenishment properties.

BCL-2:

Bcl-2 has been scrutinized by numerous specialists in light of its part inside cancer cells as a proto-oncogene. Bcl-2 is over-communicated in numerous cancer, accelerating an anticipation of apoptosis. It has been indicated that this impediment to apoptosis because of over-articulation of Bcl-2 outcomes in an expanded number of stem cell in vivo [35]. This proposes that apoptosis assumes a part in directing the microenvironments of stem cell [36]. Thusly, the Bcl-2 signaling pathway is extremely imperative to the survival of stem cells, particularly cancer stem cells, due to the overexpression of Bcl-2 in tumors [37].



Figure 2: Possible "stem cell miRNAs" that tweak "stem cell genes" identified with tumor stem cell. Certain miRNAs have been demonstrated to be deviantly communicated in cancer. OncomiRs, which start cancer advancement, are over-expressed. TSmiRs, which avoid tumor improvement, are diminished. These miRNAs manage genes that are ensnared in stem cells. The deviant expression of these potential "stem cell miRNAs" in cancer prescribes that dysregulation of "stem cell genes" expedites expanded levels of self-restoration and diminished levels of apoptosis inside tumor stem cells.

BOND BETWEEN MIRNA AND CANCER STEM CELLS:

Deviant expressions of miRNAs are associated with human cancer, for example cancer. Tumors examined by miRNA profiling have demonstrated significantly diverse miRNA profiles (for mature or antecedent miRNAs) contrasted and standard cells from the same tissue [38]. It has likewise been indicated by influencing confirmation that miRNAs are vital variables in stem cell science. Thirty-six extraordinary miRNAs (from 32 stem-loops) have been identified by cDNA cloning to be specifically communicated in human embryonic stem cell with respect to their separated embryoid bodies [13]. The evident parallel that could be drawn is that stem cells show miRNA representation profiles reminiscent of cancer cells [19]. There is additionally over-whelming confirmation that a different subpopulation of cancer cells has the capability of self-recharging, and subsequently demonstration as cancer stem cells inside tumors [39]. Realizing that abnormal gene capacity and expression are crux aspects in cancer, it is imagined that gained epigenetic irregularities in hereditary changes, bringing on dysregulation in tumor stem cells. This dysregulation permits them to escape the confinements of the stem cell specialty, bringing about unrestricted self-reestablishment capability and potential. It is accepted that micro environmental elements or indicates elucidate the epigenetic variations from the norm cancer stem cell. These signals meddle with gene expressions, bringing about the hushing of a few genes. Consequently, there must be some underlying sub-cellular process that explains this dysregulation in cancer stem cells.

One pathway of investigative pertinence is the RNAi pathway. The RNAi pathway is paramount in light of the fact that it hushes gene articulation at translation or translation. MiRNAs have been ensnared in the RNAi pathway by contrarily regulating gene and protein interpretation at the post-transcriptional level. Changed interpretation of specific miRNA genes contributes to the start and movement of cancer [11]. Interruption of miRNA expression levels in tumor cells might come about because of contorted epigenetic regulation of miRNA expression, aberrances miRNA preparing genes or proteins, and the area of miRNAs at cancer cohorted genomic areas [40]. Decidedly, miRNAs assume a discriminating part in carcinogenesis and oncogenesis. Rising proof recommends that certain atypical miRNA expression levels cause cancer

stem cell dysregulation, bringing about unrestricted self-restoration and cancer movement. Subsequently, miRNA interpretation is a basic key to cancer stem cell dysregulation.

What's more, various miRNAs have been identified inside cancer to capacity as either oncogenes or tumor silencers [41]. These miRNAs offer incredible guarantee for tumor therapy since they may have the possibility to control deviant miRNA expression. In this manner, miRNA therapy could be an effective apparatus to address cancer stem cell dysregulation and its resulting self-renewal and cancer progression in patients



Figure 3: Connection between miRNA and cancer stem cells. Atypical outflows of miRNAs, either as oncogenic or tumor silencer miRNAs, can expedite dysregulation of stem cell genes, bringing about expanded self-recharging potential and debilitated separation in cancer stem cell. This dysregulation thusly brings about carcinogenesis and oncogenesis. It is recommended that miRNA antagonists can knockdown the impacts of oncogenic miRNAs and miRNA imitates can restore the capacities of tumor silencer miRNAs. Hence, miRNA could be a fundamental apparatus in tending to tumor stem cell dysregulation. MiRNA-based molecular therapy could hold incredible restorative potential against cancer progression, resistance, and backslide.

Illustrations Support the function of "Stem Cells miRNAs" in Oncogenesis and the Consequences in Molecular Cancer Therapy:

It is clear that these "stem cell miRNAs" play an imperative reason in the regulation of the talked over "stem cell genes" and their consequent indicating pathways in disease. Figure 2 gives a schematic perspective of these "stem cell miRNAs" and their communications with "stem cell genes" in cancer stem cells.

These "stem cell miRNAs" help the potential connection between miRNAs and cancer stem cells. Figure 3 layouts this potential connection between miRNAs and cancer stem cells. The greater part of these cases recommend that miRNAs have a crucial capacity in carcinogenesis and oncogenesis by controlling self-restoration and apoptosis by means of cancer stem cell signaling pathways as oncogenes or tumor silencers, individually. These oncogenic and tumor silencer miRNAs accelerate an improved understanding of cancer malignancy stem cell science, and in this manner, a more excellent learning of how growth begins and advances into threatening tumor arrangement. Dysregulation of cancer stem cells permits them to departure the limitations of the stem cell corner, bringing about unrestricted self-recharging capacity and potential, which brings about further cancer improvement and imperviousness to current medications. It has been exhibited that unusual expression of certain miRNAs are not just joined with cancer by and

large, yet these atypical miRNA expression are included in cancer stem cell dysregulation. Useful investigations of specific miRNAs inside the cancer stem cells of different tumors are urgent for the clarification of the mechanisms behind oncogenesis in different cancer [42] A few miRNAs are up-controlled in cancer stem cells and enactment as oncogenes. These oncogenes ought to be focused with medicines that knockdown their expression. Different miRNAs stifle cell burgeoning by nature, filling in as tumor silencers, yet are down-directed in cancer stem cell, bringing about cancer progression. These tumor silencers ought to be focused with treatments that restore their tumor silencer capacities inside the cancer stem cells. Consequently, tending to these irregular miRNA articulation levels with molecular miRNA therapy could be a capable device to handle tumor stem cell dysregulation and, consequently, oncogenesis.

MicroRNA Therapeutics:

MiRNAs are extremely guaranteeing as restorative focuses for against cancer medications since their unusual expression are joined to tumor stem cell dysregulation and, subsequently, oncogenesis. MiRNA-based molecular cancer therapy may as well dispose of the self-reestablishment capacities of the cancer stem cell and significantly lessen the resistance for latest tumor medicine, and additionally backslide in cancer patients.

Improvement of miRNA/RNAi-based therapeutics requires some discriminating exploratory steps, which incorporate:

[1] miRNA profiling of cancer versus solid tissue, and particularly cancer stem cells versus the separated cells,

[2] useful investigation of dysregulated miRNAs, and

[3] in vivo studies with utilization of diverse RNAi-based restorative strategies address deviant miRNA expressions [19].

For oncogenic miRNAs, which push cancer when over-communicated, an antagomiR ought to be utilized to square the impacts of the OncomiRs [43]. The antagomiR thumps down the oncogenic properties of the miRNA, bringing about cancer concealment and diminished movement. Case in point, to thump down the expression of the oncogene miR-21, an against miR-21 oligonucleotide was transfected into breast cancer MCF-7 cells. It was showed that the anit-miR-21 stifled both cell development in vitro and tumor development in a xenograft rodent demonstrates by expanding apoptosis and decreasing cell multiplication. Thusly, antagomiRs are promising as restorative focuses for oncogenic miRNA-based cancer stem cell dysregulation.

For tumor silencer miRNAs, which advertise tumor when under-communicated, miRNA copies or lentiviruses ought to be utilized to restore the tumor silencers' common potential, bringing about diminished cancer advancement. Case in point, to represent miR-34 and its tumor silencer abilities, we transfected miR-34 emulates into cancer cells, and the copy was demonstrated to block the cell cycle in the G1 stage, significantly expand activation of caspase-3, and thump down its downfield focuses of bcl-2, Notch, and HMGA2 [44]. The miRNA copy, in this way, restored miR-34 with its tumor suppressor potential; be that as it may, the transfection of the miR-34 mimics can just keep going several days and the lifelong living impacts were not watched quite viably. To beat this difficulty, the cancer cells were tainted with a lentivirus that communicated miR-34a. This produced stable cells expression miR-34a. The lentiviral miR-34a was discovered to have the capacity to hinder cancer cell development and tumor sphere development [44]. The lentiviral framework restored the tumor silencer impact of miR-34 in pancreatic cancer stem cells besides. Therefore, miRNA impersonates and lentiviral miRNAs show incredible potential in restoring tumor silencer miRNAs to adjust the dysregulation of "stem cell genes" in cancer stem cells.

The Challenge of Delivery in miRNA Therapeutics:

Notwithstanding, from a clinical/translational research perspective, for the miRNA-based therapeutics to be adequate, the efficient and utilitarian delivery of miRNA imitates or alternately rivals to tumor remains an extraordinary test.

Current methodologies to convey gene and RNAi-based therapeutics utilize either viral or non-viral vector frameworks [45]. Viral vector-controlled techniques show high gene exchange efficiency yet are deficient in numerous areas. The confinements of a viral methodology are identified with their absence of tumor focusing on and to lingering viral components that could be immunogenic, cytopathic, or recombinogenic [45]. Non-viral gene exchange vectors could dodge a percentage of the issues connected with viral vectors. Advance has been made to improving non-viral, pharmaceutical formulation of gene therapeutics for in vivo human therapy, especially cationic liposome-intervened gene exchange frameworks [43]. Cationic liposomes are made out of emphatically charged lipid bilayers and could be complexed to contrarily charged, bare DNA by straightforward blending of lipids and DNA such that the resulting intricate (lipoplex) has a net positive charge [46]. The lipoplex is effortlessly bound and brought up by cells with generally high transfection efficiency. Characteristics of cationic liposomes that make them flexible and magnetic for DNA delivery incorporate: straightforwardness of arrangement; the capability to complex vast measures of DNA; flexibility being used with

any sort and size of DNA or RNA; the capability to transfect numerous distinctive sorts of cells, incorporating non-separating cells; and absence of immunogenicity or bio hazardous movement [46]. There are different clinical trials now under-way utilizing cationic liposomes for gene delivery, and liposomes for delivery of chemotherapeutics, for example doxorubicin are as of now available for bosom cancer chemotherapy.

One burden of cationic liposomes is that they need tumor specificity and have generally flat transfection efficiencies as contrasted with viral vectors. Be that as it may, this might be breathtakingly expanded when the lipoplexes bear a ligand distinguished by a cell surface receptor [44]. Receptor interceded endocytosis stands for a quite efficient innerization pathway in eukaryotic cells. The vicinity of a ligand on a lipoplex expedites the passage of DNA into cells through initial binding of ligand by its receptor on the cell surface emulated by disguise of the bound lipoplex [42]. When disguised, sufficient DNA escapes the endocytic pathway to be communicated in the cell core. Mixtures of ligands have been examined for their lipoplex-focusing on capacity [89, 90].

As of late, we advanced tumor-specific, ligand-focusing on, self-amassed, nanoparticle–DNA lipoplex frameworks intended for systemic gene therapy of cancer. These Nano-vector frameworks utilize transferrin (Tf) or scFv against transferrin receptor (TfR), which is over-communicated in the majority of human cancer, as tumor-focusing ligand [46]. The point when utilizing Tf as a focusing on ligand, we acquired the self-gathered Nano vectors at the sizes of 50–90 nm, with profoundly minimal structure and most beloved surface charge [47]. These Nano vectors have novel nanostructure that looks like an viral infection molecule with a thick center wrapped by a layer covered with Tf atoms spiking on the surface. This Nano vector framework shows guaranteeing efficiency and specificity in focused delivery of different genes and anti-sense oligonucleotides to cancer in vivo yet not typical tissues [49]. Systemic p53 gene therapy utilizing these Nano vector frameworks exhibited lifelong remedial efficacy in animal's models of human cancer [48]. Tf-and TfR-scFv focused on Nano vectors were recently affirmed by the FDA for clinical testing, and the first Phase-I clinical trial for non-viral systemic p53 gene therapy treatment is continuous (www.clinicaltrials.gov). The accomplishment of these Nano vectors for systemic p53 gene therapy treatment, and more latestly Her-2 siRNA therapy treatment [48], furnish a guaranteeing, tumor-focused delivery framework for novel RNAi-based therapies, for example miRNA-therapeutics talked over above.

CONCLUSIONS:

Irregular miRNA expressions are associated with cancer stem cell dysregulation. This dysregulation prompts the start, advancement, and movement of cancer. Consequently, molecular miRNA help is exceptionally significant to tending to oncogenesis interfaced with cancer stem cell dysregulation. Therefore, future research ought to be pointed at accepting the connection between miRNAs and cancer stem cell, researching miRNAs' part in cancer stem cells self-restoration pathways, and additionally considering restorative potential of miRNAs against cancer movement, safety, and backslide.

ACKNOWLEDGMENTS:

The author acknowledges Dr Madhulika Kabra, Professor of Pediatrics, AIIMS Hospital for her critical help.

DISCLOSURE:

The author reports no conflicts of interest in this work

REFERENCES:

1. Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A. 2003;100:9779–84.
2. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al.MicroRNA genes are transcribed by RNA polymerase II. EmboJ. 2004;23:4051–60.
3. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA. 2004;10:1957–66.
4. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 2004;18:3016–27.
5. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003;17:3011–6.
6. Haase AD, Jaskiewicz L, Zhang H, Laine S, Sack R, Gatignol A,et al. TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing. EMBO Rep. 2005;6:961–7.
7. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302:1–12.
8. Croce CM, Calin GA. miRNAs, cancer, and stem cell division.Cell. 2005;122:6–7.

9. Rigoutsos I. New tricks for animal microRNAS: targeting of amino acid coding regions at conserved and nonconserved sites. Cancer Res. 2009;69:3245–8.
10. Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, et al.Human embryonic stem cells express a unique set of micro- RNAs. Dev Biol. 2004;270:488–98.
11. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, et al. Dicer is essential for mouse development. Nat Genet.2003;35:215–7.
12. Kanellopoulou C, Muljo SA, Kung AL, Ganesan S, Drapkin R, Jenuwein T, et al. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. GenesDev. 2005;19:489–501.
13. Hatfield SD, Shcherbata HR, Fischer KA, Nakahara K, Carthew RW, Ruohola-Baker H. Stem cell division is regulated by the microRNA pathway. Nature. 2005;435:974–8.
14. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif. 2003;36(Suppl 1):59–72.
15. Farnie G, Clarke RB. Mammary stem cells and breast cancer—role of Notch signalling. Stem Cell Rev. 2007;3:169–75.
16. Papagiannakopoulos T, Kosik KS. MicroRNAs: regulators of oncogenesis and stemness. BMC Med. 2008;6:15.
17. Dick JE. Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol. 1996;8:197–206.
18. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene. 2004;23:7274–82.
19. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593–8.
20. Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007;67:8980–4.
21. Wicha MS. Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res. 2006;12:5606–7.
22. Zhang M, Behbod F, Atkinson RL, Propertiesis MD, Kittrell F, Edwards D, et al. Identification of tumor-initiating cells in a p53- null mouse model of breast cancer. Cancer Res. 2008;68:4674–82.
23. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, et al. Stem cell-related "self-renewal" signature and high epidermal cancer factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26:3015–24.
24. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.
25. Zencak D, Lingbeek M, Kostic C, Tekaya M, Tanger E, Hornfeld D, et al. Bmi1 loss produces an increase in astroglial cells and a decrease in neural stem cell population and proliferation. J Neurosci. 2005;25:5774–83.
26. Fasano CA, Dimos JT, Ivanova NB, Lowry N, Lemischka IR, Temple S. shRNA knockdown of Bmi-1 reveals a critical role for p21-Rb pathway in NSC self-renewal during development. Cell Stem Cell. 2007;1:87–99.
27. Zhang Y, Kalderon D. Hedgehog acts as a somatic stem cell factor in the Drosophila ovary. Nature. 2001;410:599–604.
28. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003;423:409–14.
29. Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, et al.Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets. 2004;4:653–71.
30. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657–67.
31. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer. 2007;7:899–910.
32. Abe N, Watanabe T, Suzuki Y, Matsumoto N, Masaki T, Mori T, et al. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer. 2003;89:2104–9.
33. Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, et al. HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog. 2007;46:503–11.
34. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, et al.Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res.2006;66:6063–71.
35. Domen J, Gandy KL, Weissman IL. Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation. Blood. 1998;91:2272–82.

36. Domen J, Cheshier SH, Weissman IL. The role of apoptosis in the regulation of hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation potential. J Exp Med. 2000;191:253–64.

37. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE. 2009;4:e6816.

38. Calin GA, Croce CM. MicroRNA signatures in human cancers.Nat Rev Cancer. 2006;6:857–66.

39. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004;101:14228–33.

40. Wiemer EA. The role of microRNAs in cancer: no small matter.Eur J Cancer. 2007;43:1529–44.

41. Hatfield S, Ruohola-Baker H. microRNA and stem cell function. Cell Tissue Res. 2008;331:57–66.

42. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with 'antagomiRs'. Nature. 2005;438:685–9.

43. Pirollo KF, Xu L, Chang EH. Non-viral gene delivery for p53. Curr Opin Mol Ther. 2000;2:168–75.

44. Xu L, Pirollo KF, Chang EH. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J Control Release. 2001;74:115–28.